Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Reid Waldman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Beta
- 1.23
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 241.95
Financials
MANE has only 5 quarterly periods on file — the charts below show the full history available.
Net Income
$-23.50MEBITDA
$-29.55MFree Cash Flow
$-14.51MEPS (diluted)
$-0.58Shares Outstanding (diluted)
40.44M-79.9%Operating Expenses
$29.55MCash & Debt
$819.89MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-70.00M | $-2.38 |
| 2024 | $0.00 | $-26.49M | $-0.14 |
| 2023 | $0.00 | $-16.49M | $-0.08 |
Valuation
MANEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-64.29%Social Signal Score
Mentions (6)
- News (RSS)seekingalpha·26d ago·Neutral
Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
View source ↗ - Newsbusinesswire.com·32d ago·Negative
Veradermics to Present at Upcoming September Investor Conferences NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi…
View source ↗ - News (RSS)investing·42d ago·Neutral
Why is Veradermics stock sliding today?
View source ↗ - News (RSS)investing·42d ago·Neutral
Veradermics stock falls following insider share sale
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
Veradermics reports Q2 results
View source ↗ - Newsbusinesswire.com·56d ago·Negative
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress. “In the second quarter of 2026, we made significa
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.59 per share
Typical surprise +10.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.58 vs $-0.65beat
- Tue, May 12$-1.32 vs $-0.56miss
- Wed, Feb 25$-1.63 vs $-1.81beat
Estimates and results for MANE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in MANE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.